Stanford cancer-fighting spinout to Genentech: 'Don't eat me'

Cancer hijacks a signal to avoid detection and destruction by the immune system. Forty Seven believes its drug, which now will enter trials in combination with Genentech and Merck KGaA "checkpoint inhibitors," will turn the immune system to eat the cancer cells.